Srinivas Akkaraju

Director

Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +37.1% from execution and +27.8% from disclosure (delay-adjusted; derived). The largest single filing was $18.8M of SRRK (500,439 sh across 6 lots, as filed), executed Oct 3 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+37.1%

avg across 11 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+27.8%

same 11 filings, from disclosure

Filings, ttm

12 buys · 1 sells · 2 late

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$57.0M

shares × price, as filed

Last traded

Sep 8

Filed Sep 9

Median ADV $31.6M across their filed names

Impact on $10,000 · 12M

$16,234 (+62.3%)

S&P 500 $11,723 (+17.2%) · 45.1 pts ahead

Srinivas Akkaraju S&P 500

Compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $81.7M Sells $35.4M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 13 filings

Sector per market data · by filing · past 12 months

Most traded names

ALMS

Alumis Inc. ALMS · 9 buys · 1 sell 9 filings SRRK

Scholar Rock Holding Corporation SRRK · 2 buys · 1 sell 3 filings KLRS

Kalaris Therapeutics, Inc. KLRS · 2 buys · 0 sells 2 filings MLYS Mineralys Therapeutics, Inc. MLYS · 2 buys · 0 sells 2 filings NGNE

Neurogene Inc. NGNE · 1 buy · 0 sells 1 filing

Recent filings

NGNEPURCHASE Neurogene Inc. View filing → $1.2M
46,770 sh across 3 lots
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET SRRKSALE Scholar Rock Holding Corporation View filing → $34.4M
1,175,713 sh across 3 lots
Exec Oct 7 2024
Filed Oct 7 2024 · 5:30 PM ET